Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...

Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease ...

Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development ...